DG
SRPT icon

Delek Group’s Sarepta Therapeutics SRPT Stock Holding History

Delek Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$7.42M Buy
+50,000
New +$6.08M 0.29% 97
2019
Q1 		– Sell
-30,850
Closed -$3.46M – 236
2018
Q4 		$3.46M Buy
+30,850
New +$3.86M 0.16% 140
2018
Q2 		– Sell
-26,998
Closed -$2M – 265
2018
Q1 		$2M Sell
26,998
-10,000
-27% -$667K 0.1% 156
2017
Q4 		$2.06M Buy
+36,998
New +$1.96M 0.11% 152

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Delek Group's SRPT Position: Q2 2019 in Review

Delek Group opened a new position in Sarepta Therapeutics (SRPT) in Q2 2019: 50,000 shares worth $7.42M. The stake represents 0.29% of the portfolio and ranks #97 among its holdings. This is a return to the name: Delek Group previously reported a position in SRPT as recently as Q4 2018.

Delek Group first reported a position in SRPT in Q4 2017 and has held it in 4 quarters since. 365 funds tracked by Wall St. Rank hold SRPT as of Q2 2019.

  • Delek Group held 50,000 shares of Sarepta Therapeutics worth $7.42M as of Q2 2019.
  • Sarepta Therapeutics was a new Delek Group position in Q2 2019.
  • Sarepta Therapeutics made up 0.29% of Delek Group's portfolio in Q2 2019, its #97 holding.
  • Delek Group first reported a position in Sarepta Therapeutics in Q4 2017 and has held it in 4 quarters since.
  • 365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2019.

Based on Delek Group's 13F filing for Q2 2019, filed 8 Aug 2019.